(Q33922853)

30 July 2017

1 reference

title

Fibrinogen receptor antagonists: design and clinical applications (English)

1 reference

30 July 2017

Eldred CD

1

1 reference

30 July 2017

Judkins BD

series ordinal

2

1 reference

30 July 2017

publication date

1 January 1999

1 reference

Progress in medicinal chemistry

30 July 2017

published in

1 reference

30 July 2017

volume

36

1 reference

30 July 2017

page(s)

29-90

1 reference

Role of platelets in thrombosis and hemostasis.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Platelet activation mechanisms and markers in arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Dynamic regulation of integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Platelets and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Structural and functional aspects of RGD-containing protein antagonists of glycoprotein IIb-IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Ligand binding to GPIIb-IIIa: a status report

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

GPIIb-IIIa: the responsive integrin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Integrins: emerging paradigms of signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

The pharmacology of the integrins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Role of the platelet integrin glycoprotein IIb-IIIa in intracellular signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Low molecular weight, non-peptide fibrinogen receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

In vivo models of arterial thrombosis and thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Cyclic RGD peptide analogues as antiplatelet antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Platelet receptor recognition domains on the alpha chain of human fibrinogen: structure-function analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa recepto

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

SC-54684A: an orally active inhibitor of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Discovery of an orally active non-peptide fibrinogen receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine prepa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Biological evaluation of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: effects of chelators on biological properties of [99mTc]chelator-peptide conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

"Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Clinical pharmacology of eptifibatide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Role of platelets in restenosis after percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

von Willebrand factor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970045-6

7 January 2021

10.1016/S0079-6468(08)70045-6

Identifiers

DOI

0 references

1 reference